Product
TSR-022
3 clinical trials
9 indications
Indication
CancerIndication
Metastatic CancerIndication
Advanced CancerIndication
Solid TumorIndication
Non Small Cell Lung Cancer MetastaticIndication
Non-Small Cell Lung Cancer Stage IIIBIndication
Lung CancerIndication
Hepatocellular carcinomaIndication
Hepatocellular CarcinomaClinical trial
Phase 1b Dose-Finding Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 in Patients With Advanced or Metastatic CancerStatus: Active (not recruiting), Estimated PCD: 2020-02-26
Clinical trial
Phase II Study of TSR-022 (Cobolimab) in Combination With TSR-042 (Dostarlimab) for the Treatment of Advanced Hepatocellular CarcinomaStatus: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)Status: Recruiting, Estimated PCD: 2025-04-09